| Literature DB >> 34815596 |
Rachael McIlroy1,2,3, David W Nelson3, B Cherie Millar1,2, Alan Murphy2, Juluri R Rao3, Damian G Downey1,4, John E Moore1,2.
Abstract
Antimicrobial resistance (AMR) has now emerged as a major global public health problem. Certain bacterial pathogens, particularly Gram negative organisms associated with patients with cystic fibrosis (CF), have become resistant to several classes of antibiotics resulting in pan-resistance, which creates a clinical treatment dilemma. This study wished to explore the production of antibacterial extracellular metabolites from plant pathogenic fungi. Fungal Culture Extracts (FCEs) were prepared from 10 fungi (Armillaria gallica, Clitocybe nebularis, Fusarium coeruleum, Fusarium oxysporum, Fusarium poae, Hymenoscyphus fraxineus, Nectria fuckeliana, Phytophthora infestans, Phytophthora ramorum, Postia placenta), which were tested for activity against the CF pathogens, Pseudomonas aeruginosa (PA) (n=8), Burkholderia cenocepacia (n=2) and Stenotrophomonas maltophilia (n=2). In addition, FCE were assessed for their ability to alter antibiotic susceptibility in PA (n=8), with six antipseudomonal antibiotics (ceftazidime, ciprofloxacin, colistin, meropenem, piperacillin/tazobactam, tobramycin). None of the FCEs showed inhibitory activity to the 12 bacterial isolates tested, with the exception of the FCE from Postia placenta, which showed inhibition against all 12 bacteria. An antagonistic interaction was observed, where a statistically significant decrease in mean zone sizes was noted with Armillaria gallica (p=0.03) and Phytophthora infestans (p=0.03) FCEs and their interaction with the fluoroquinolone antibiotic, ciprofloxacin. Given the increase in clinical morbidity and mortality associated with chronic lung infections with Pseudomonas aeruginosa, Burkholderia cenocepacia and Stenotrophomonas maltophilia, coupled with the difficulty in treating such chronic infection due to overwhelming antimicrobial resistance, any novel substance showing inhibition of these organisms merits further investigation as a potential future antimicrobial agent, with potential clinical therapeutic application.Entities:
Mesh:
Substances:
Year: 2021 PMID: 34815596 PMCID: PMC8581687
Source DB: PubMed Journal: Ulster Med J ISSN: 0041-6193
Description of environmental macro- and filamentous plant pathogenic fungi examined in this study
| Environmental fungi | Common name | Taxonomy (Phylum) | Description | Previous antimicrobial reports |
|---|---|---|---|---|
|
| Bulbous Honey Fungus/White Rot Fungus |
| Macrofungus.Plant pathogen; Root rot of garden trees | None |
|
| Clouded Funnel/Clouded Agaric |
| Macrofungus. Saprophytic fungus found in under conifers | Antifungal activity [4] |
|
| None | Ascomycota | Filamentous fungus. Plant pathogen causing dry rot of potatoes | None |
|
| None | Ascomycota | Filamentous fungus. Plant pathogen causing a variety of wilt diseases | Antibiotic activity [5] |
|
| None | Ascomycota | Filamentous fungus. Plant pathogen causing Head Blight in wheat | Antibiotic activity [6] |
|
| None | Ascomycota | Filamentous fungus. Plant pathogen causing Ash Dieback disease in Ash trees ( | None |
|
| None | Ascomycota | Saprophytic fungus and plant pathogen causing apple canker, Nectria twig blight and coral spot in orchards. Flute canker. | None |
|
| Oomycete or potato blight mould | Oomycota | Filamentous fungus. Plant pathogen causing potato blight disease | Antibiotic activity [7] |
|
| Oak blight | Oomycota | Filamentous fungus: Plant pathogen causing sudden oak death | None |
|
| Brown rot disease | Basidiomycota | Macrofungus. Plant pathogen causing brown rot disease. | None |
Figure 1Inhibition of four isolates of Pseudomonas aeruginosa isolated from sputum of patients with cystic fibrosis with Fungal Culture Extracts from the Brown Rot fungus, Postia placenta
Mueller-Hinton Control (no Fungal Cultural Extract added)
| Isolate | Zone of inhibition (mm) | |||||
|---|---|---|---|---|---|---|
| Ceftazidime CAZ30 | Tobramycin TOB10 | Colistin CT10 | Meropenem MEM10 | Ciprofloxacin CIP5 | Piperacillin/Tazobactam TZP110 | |
| PA CF/05/11 | 30 | 26 | 16 | 28 | 26 | 14 |
| PA CF/96/06 | 28 | 28 | 8 | 0 | 10 | 28 |
| PA BC/07/658 | 0 | 22 | 12 | 34 | 32 | 28 |
| PA CF/96/49 | 22 | 24 | 14 | 32 | 18 | 18 |
| PA CF/05/49 | 36 | 24 | 16 | 34 | 38 | 24 |
| PA CF/96/33 | 34 | 30 | 18 | 18 | 10 | 38 |
| PA CF/05/56 | 26 | 28 | 18 | 0 | 32 | 30 |
| PA 91/BC/07 | 16 | 24 | 0 | 26 | 36 | 16 |
| Mean | 24 | 25.75 | 12.75 | 21.5 | 25.25 | 24.5 |
Armillaria gallica
| Isolate | Zone of inhibition (mm) | |||||
|---|---|---|---|---|---|---|
| Ceftazidime CAZ30 | Tobramycin TOB10 | Colistin CT10 | Meropenem MEM10 | Ciprofloxacin CIP5 | Piperacillin/Tazobactam TZP110 | |
| PA CF/05/11 | 0 | 28 | 0 | 28 | 28 | 34 |
| PA CF/96/06 | 20 | 30 | 18 | 24 | 0 | 22 |
| PA BC/07/658 | 0 | 24 | 12 | 28 | 30 | 14 |
| PA CF/96/49 | 18 | 24 | 14 | 34 | 0 | 18 |
| PA CF/05/49 | ND | 0 | 16 | 38 | 32 | 26 |
| PA CF/96/33 | ND | 32 | 18 | 16 | 0 | 32 |
| PA CF/05/56 | 36 | 28 | 0 | 36 | 28 | 26 |
| PA 91/BC/07 | 16 | 22 | 12 | 26 | 34 | 16 |
| Mean | 15 | 23.5 | 11.25 | 28.75 | 19 | 23.5 |
|
| 0.38 | 0.50 | 0.70 | 0.21 | 0.03 | 0.78 |
|
| 0.42 | |||||
Table 2a-f: Zones of inhibition created by six antibiotics on PA strains (n=8) when grown on Muller-Hinton agar supplemented with 10% [v/v] Fungal Culture Extracts (FChs).
The tables are colour coded depending on whether the strain showed sensitivity, intermediate resistance or resistance to the antibiotic according to CLSI criteria. If a strain susceptibility classification was altered when grown on a media including fungal supernatant when compared to the Standard Muller Hinton control (Table 2a), the zone of inhibition is outlined. Zones of inhibition where analysed using a two-tailed paired student t-test with significant p values (p=<0.05) noted in red. Tables titled according to FCE incorporated.
| Key as per CLSI standards | Sensitive | Intermediately resistant | Resistant | Different from Control Plate | PA = |
Nectria fuckeliana
| Isolate | Zone of inhibition (mm) | |||||
|---|---|---|---|---|---|---|
| Ceftazidime CAZ30 | Tobramycin TOB10 | Colistin CT10 | Meropenem MEM10 | Ciprofloxacin CIP5 | Piperacillin/Tazobactam TZP110 | |
| PA CF/05/11 | 46 | 0 | 20 | 36 | 28 | 34 |
| PA CF/96/06 | 28 | 28 | 18 | 28 | 0 | 26 |
| PA BC/07/658 | 0 | 20 | 14 | 10 | 32 | 0 |
| PA CF/96/49 | 22 | 20 | 10 | 32 | 16 | 0 |
| PA CF/05/49 | 28 | 22 | 12 | 40 | 32 | 26 |
| PA CF/96/33 | 0 | 34 | 14 | 20 | 8 | 24 |
| PA CF/05/56 | 20 | 32 | 10 | 36 | 30 | 36 |
| PA 91/BC/07 | 18 | 24 | 0 | 26 | 32 | 20 |
| Mean | 20.25 | 22.5 | 12.25 | 28.5 | 22.25 | 20.75 |
|
| 0.48 | 0.37 | 0.81 | 0.32 | 0.06 | 0.51 |
|
| 0.50 | |||||
Phytophthora infestans
| Isolate | Zone of inhibition (mm) | |||||
|---|---|---|---|---|---|---|
| Ceftazidime CAZ30 | Tobramycin TOB10 | Colistin CT10 | Meropenem MEM10 | Ciprofloxacin CIP5 | Piperacillin/Tazobactam TZP110 | |
| PA CF/05/11 | 36 | 30 | 14 | 26 | 0 | 36 |
| PA CF/96/06 | 0 | 28 | 0 | 24 | 0 | 0 |
| PA BC/07/658 | 26 | 24 | 0 | 20 | 0 | 28 |
| PA CF/96/49 | 22 | 0 | 14 | 30 | 0 | 0 |
| PA CF/05/49 | ND | 24 | 16 | 36 | 26 | 0 |
| PA CF/96/33 | 28 | 32 | 0 | 16 | 8 | 26 |
| PA CF/05/56 | 28 | 32 | 0 | 36 | 36 | 26 |
| PA 91/BC/07 | 18 | 26 | 14 | 26 | 36 | 20 |
| Mean | 22.57 | 24.50 | 7.25 | 26.75 | 13.25 | 17.00 |
|
| 0.96 | 0.72 | 0.19 | 0.39 | 0.03 | 0.24 |
|
| 0.10 | |||||
Fusarium oxysporum
| Isolate | Zone of inhibition (mm) | |||||
|---|---|---|---|---|---|---|
| Ceftazidime CAZ30 | Tobramycin TOB10 | Colistin CT10 | Meropenem MEM10 | Ciprofloxacin CIP5 | Piperacillin/Tazobactam TZP110 | |
| PA CF/05/11 | 38 | 30 | 8 | 28 | 30 | 34 |
| PA CF/96/06 | 26 | 34 | 0 | 24 | 0 | 28 |
| PA BC/07/658 | 16 | 24 | 0 | 14 | 36 | 0 |
| PA CF/96/49 | 18 | 24 | 14 | 32 | 0 | 0 |
| PA CF/05/49 | 28 | 26 | 16 | 36 | 26 | 26 |
| PA CF/96/33 | 30 | 32 | 0 | 0 | 0 | 28 |
| PA CF/05/56 | 32 | 0 | 18 | 36 | 30 | 26 |
| PA 91/BC/07 | 0 | 0 | 14 | 26 | 30 | 18 |
| Mean | 23.5 | 21.25 | 8.75 | 24.5 | 19 | 20 |
|
| 0.89 | 0.37 | 0.28 | 0.67 | 0.06 | 0.41 |
|
| 0.13 | |||||
Clitocybe nebularis
| Isolate | Zone of inhibition (mm) | |||||
|---|---|---|---|---|---|---|
| Ceftazidime CAZ30 | Tobramycin TOB10 | Colistin CT10 | Meropenem MEM10 | Ciprofloxacin CIP5 | Piperacillin/Tazobactam TZP110 | |
| PA CF/05/11 | 36 | 28 | 10 | 30 | 28 | 0 |
| PA CF/96/06 | 20 | 28 | 22 | 20 | 0 | 26 |
| PA BC/07/658 | 0 | 22 | 14 | 26 | 32 | 28 |
| PA CF/96/49 | 22 | 0 | 14 | 34 | 18 | 26 |
| PA CF/05/49 | 26 | 22 | 0 | 36 | 0 | 28 |
| PA CF/96/33 | 26 | 34 | 20 | 20 | 0 | 26 |
| PA CF/05/56 | 36 | 0 | 16 | 38 | 32 | 28 |
| PA 91/BC/07 | 20 | 24 | 14 | 28 | 36 | 18 |
| Mean | 23.25 | 19.75 | 13.75 | 29 | 18.25 | 22.5 |
|
| 0.78 | 0.22 | 0.78 | 0.19 | 0.18 | 0.48 |
|
| 0.48 | |||||